|
1
|
Chow LQM: Head and neck cancer. N Engl J
Med. 382:60–72. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wyss A, Hashibe M, Chuang SC, Lee YC,
Zhang ZF, Yu GP, Winn DM, Wei Q, Talamini R, Szeszenia-Dabrowska N,
et al: Cigarette, cigar, and pipe smoking and the risk of head and
neck cancers: Pooled analysis in the International head and neck
cancer epidemiology consortium. Am J Epidemiol. 178:679–690. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chaturvedi AK, Engels EA, Pfeiffer RM,
Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M,
Cozen W, et al: Human papillomavirus and rising oropharyngeal
cancer incidence in the United States. J Clin Oncol. 29:4294–4301.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gillison ML, Chaturvedi AK, Anderson WF
and Fakhry C: Epidemiology of human papillomavirus-positive head
and neck squamous cell carcinoma. J Clin Oncol. 33:3235–3242. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pfister DG, et al: NCCN clinical practice
guideline in oncology-head and neck cancers, version 1. 2019 March
6–2019.2019.
|
|
7
|
Cramer JD, Burtness B, Le QT and Ferris
RL: The changing therapeutic landscape of head and neck cancer. Nat
Rev Clin Oncol. 16:669–683. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cramer JD, Burtness B and Ferris RL:
Immunotherapy for head and neck cancer: Recent advances and future
directions. Oral Oncol. 99:1044602019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
NCI, . SEER Database: Cancer Stat Facts:
Oral cavity and pharynx cancer, laryngeal cancer. 2009-2015.
|
|
10
|
Cohen EEW, LaMonte SJ, Erb NL, Beckman KL,
Sadeghi N, Hutcheson KA, Stubblefield MD, Abbott DM, Fisher PS,
Stein KD, et al: American cancer society head and neck cancer
survivorship care guideline. CA Cancer J Clin. 66:203–239. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pulte D and Brenner H: Changes in survival
in head and neck cancers in the late 20th and early 21st century: A
period analysis. Oncologist. 15:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kalyankrishna S and Grandis JR: Epidermal
growth factor receptor biology in head and neck cancer. J Clin
Oncol. 24:2666–2672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bossi P, Resteghini C, Paielli N, Licitra
L, Pilotti S and Perrone F: Prognostic and predictive value of EGFR
in head and neck squamous cell carcinoma. Oncotarget.
7:74362–74379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Trivedi S and Ferris RL: Epidermal growth
factor receptor-targeted therapy for head and neck cancer.
Otolaryngol Clin North Am. 54:743–749. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Forastiere AA and Burtness BA: Epidermal
growth factor receptor inhibition in head and neck cancer-more
insights, but more questions. J Clin Oncol. 25:2152–2155. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saba NF, Chen ZG, Haigentz M, Bossi P,
Rinaldo A, Rodrigo JP, Mäkitie AA, Takes RP, Strojan P, Vermorken
JB and Ferlito A: Targeting the EGFR and immune pathways in
squamous cell carcinoma of the head and neck (SCCHN): Forging a new
alliance. Mol Cancer Ther. 18:1909–1915. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Muratori L, La Salvia A, Sperone P and Di
Maio M: Target therapies in recurrent or metastatic head and neck
cancer: State of the art and novel perspectives. A systematic
review. Crit Rev Oncol Hematol. 139:41–52. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sharafinski ME, Ferris RL, Ferrone S and
Grandis JR: Epidermal growth factor receptor targeted therapy of
squamous cell carcinoma of the head and neck. Head Neck.
32:1412–1421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bardelli A and Jänne PA: The road to
resistance: EGFR mutation and cetuximab. Nat Med. 18:199–200. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jelinek MJ and Vokes EE: Epidermal growth
factor receptor blockade in head and neck cancer: What remains? J
Clin Oncol. 37:2807–2814. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Byeon HK, Ku M and Yang J: Beyond EGFR
inhibition: Multilateral combat strategies to stop the progression
of head and neck cancer. Exp Mol Med. 51:1–14. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saada-Bouzid E and Le Tourneau C: Beyond
EGFR targeting in SCCHN: Angiogenesis, PI3K, and other molecular
targets. Front Oncol. 9:742019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pastan I, Hassan R, Fitzgerald DJ and
Kreitman RJ: Immunotoxin therapy of cancer. Nat Rev Cancer.
6:559–565. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim JS, Jun SY and Kim YS: Critical issues
in the development of immunotoxins for anticancer therapy. J Pharm
Sci. 109:104–115. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Akbari B, Farajnia S, Ahdi Khosroshahi S,
Safari F, Yousefi M, Dariushnejad H and Rahbarnia L: Immunotoxins
in cancer therapy: Review and update. Int Rev Immunol. 36:207–219.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qi Z, Qiu Y and Wang Z, Zhang H, Lu L, Liu
Y, Mathes D, Pomfret EA, Gao D, Lu SL and Wang Z: A novel
diphtheria toxin-based bivalent human EGF fusion toxin for
treatment of head and neck squamous cell carcinoma. Mol Oncol.
15:1054–1068. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Onda M, Kobayashi K and Pastan I:
Depletion of regulatory T cells in tumors with an anti-CD25
immunotoxin induces CD8 T cell-mediated systemic antitumor
immunity. Proc Natl Acad Sci USA. 116:4575–4582. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Raeber ME, Sahin D and Boyman O:
Interleukin-2-based therapies in cancer. Sci Transl Med.
14:eabo54092022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu YY, Woo JH and Neville DM: Targeted
introduction of a diphtheria toxin resistant mutation into the
chromosomal EF-2 locus of Pichia pastoris and expression of
immunotoxin in the EF-2 mutants. Protein Expr Purif. 30:262–274.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Judd NP, Winkler AE, Murillo-Sauca O,
Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB and
Uppaluri R: ERK1/2 regulation of CD44 modulates oral cancer
aggressiveness. Cancer Res. 72:365–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peraino JS, Schenk M, Li G, Zhang H,
Farkash EA, Sachs DH, Huang CA, Duran-Struuck R and Wang Z:
Development of a diphtheria toxin-based recombinant porcine IL-2
fusion toxin for depleting porcine CD25+ cells. J
Immunol Methods. 398–399. 33–43. 2013.PubMed/NCBI
|
|
32
|
Zheng Q and Wang Z, Zhang H, Huang Q,
Madsen JC, Sachs DH, Huang CA and Wang Z: Diphtheria toxin-based
anti-human CD19 immunotoxin for targeting human CD19+
tumors. Mol Oncol. 11:584–594. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fletcher EV, Love-Homan L, Sobhakumari A,
Feddersen CR, Koch AT, Goel A and Simons AL: EGFR inhibition
induces proinflammatory cytokines via NOX4 in HNSCC. Mol Cancer
Res. 11:1574–1584. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stanam A, Gibson-Corley KN, Love-Homan L,
Ihejirika N and Simons AL: Interleukin-1 blockade overcomes
erlotinib resistance in head and neck squamous cell carcinoma.
Oncotarget. 7:76087–76100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Du L, Chen X, Cao Y, Lu L, Zhang F,
Bornstein S, Li Y, Owens P, Malkoski S, Said S, et al:
Overexpression of PIK3CA in murine head and neck epithelium drives
tumor invasion and metastasis through PDK1 and enhanced TGFβ
signaling. Oncogene. 35:4641–4652. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mandal R, Şenbabaoğlu Y, Desrichard A,
Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA and
Morris LG: The head and neck cancer immune landscape and its
immunotherapeutic implications. JCI Insight. 1:e898292016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kumar P, Kumar A, Parveen S, Murphy JR and
Bishai W: Recent advances with Treg depleting fusion protein toxins
for cancer immunotherapy. Immunotherapy. 11:1117–1128. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Z, Zheng Q, Zhang H, Bronson RT,
Madsen JC, Sachs DH, Huang CA and Wang Z: Ontak-like human IL-2
fusion toxin. J Immunol Methods. 448:51–58. 2017. View Article : Google Scholar : PubMed/NCBI
|
